consistent with the development of radiographic pneumonia in this patient, clinicians pursued compassionate use of an investigational antiviral therapy. Treatment with intravenous remdesivir (a novel nucleotide analogue prodrug in development10,11) was initiated on the evening of day 7, and no adverse events were observed in association with the infusion.
The above is taken from the New England Medical Journal.
Remdesivir was a drug put forth by Gilliad Science to combat EBOLA a few years ago. It didn't work so well.
The patient involved was from Seattle area, and the head of the hospital said Remdesivir "turned his case around dramatically."
It is not yet approved and so it can only be given if the patient is close to death (compassionate use)
It cured this man who came from Central China.
Whether it will work for others----yet to be determined.
Rod Hochman the CEO of the Hospital involved said, "it is just one case, but the research seems
to be very, very positive"
